Phaseline

Targets › CXCL10

CXCL10 (C-X-C motif chemokine 10): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Immunology; next expected readout Dec 2027.

Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects. Plays thereby an important role during viral infections by stimulating the activation and migration of immune cells to the infected sites (By similarity). (UniProt, P02778)

Open in Phaseline: the race on CXCL10, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Edesa BiotechEB06
CXCL10 monoclonal antibody
CXCL10Phase 2Non-Segmental Vitiligo (NSV)Dec 2027
Changchun GeneScience PharmaceuticalGenakumab injection
CXCL10 inhibitor monoclonal antibody
CXCL10Phase 2Systemic Sclerosis Associated Interstitial Lung Disease–

Conditions

Non-Segmental Vitiligo (NSV) (1) Systemic Sclerosis Associated Interstitial Lung Disease (1)

Modalities

protein or peptide (1), small molecule (1)

Companies

Edesa Biotech (1) Changchun GeneScience Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.